| HS Code | 305200 |
| Chemical Class | Peroxygen oxidising agent (potassium peroxymonosulphate-based compound) |
| Physical Appearance | White or off-white crystalline free-flowing powder |
| Solubility | Freely soluble in water yielding opalescent solutions |
| Ph 1 Percent Solution | 2.0 to 3.2 (acidic in aqueous solution) |
| Antimicrobial Property | Broad-spectrum activity against bacteria, viruses, fungi, and spores |
| Stability | Stable under normal storage conditions in sealed, dry containers; avoid heat and direct sunlight |
| Incompatibility | Incompatible with reducing agents, heavy metals, alkalis, and organic matter |
| Veterinary Api Function | Used as an oxidising antimicrobial agent in pharmaceutical dosage forms such as tablets, injections, capsules, powders, granules, premix, and solutions |
| Storage Condition | Store in a cool, dry place in tightly closed original packaging; protect from moisture and contamination |
As an accredited Compound Peroxymonosulphate Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Compound Peroxymonosulphate Powder Veterinary Grade API: 25 kg net, packaged in sealed double polyethylene-lined fibre drums with tamper-evident closure. |
| Container Loading (20′ FCL) | 20′ FCL loading of Compound Peroxymonosulphate Powder Veterinary Grade API: packed in sealed drums/pails, palletized, secured, and containerized. |
| Shipping | Ship as non-combustible but oxidizing powder in sealed, moisture-proof containers. Avoid heat, moisture, and direct sunlight. Keep separate from organic materials and reducing agents. Use clean, dry transport vehicles with proper ventilation and secure packaging to prevent spillage. Label clearly and include safety data sheets. |
| Storage | Store in tightly sealed, original containers in a cool, dry, well-ventilated area away from direct sunlight, moisture, and heat. Keep separate from organic materials, reducing agents, and combustible substances. Ensure the area is clean and temperature-controlled, with proper labeling and restricted access, to preserve stability and safeguard veterinary product integrity throughout handling. |
| Shelf Life | Shelf life is typically 24 months when stored in original, unopened containers in a cool, dry place away from moisture and light. |
In intensive recirculating aquaculture systems and lined shrimp ponds, compound peroxymonosulphate powder veterinary grade is handled as a non-chlorine oxidative shock for dissolved organic carbon control and sulfide oxidation prior to stocking or after harvest. The triple salt, identified by CAS 70693-62-8, is broadcast dry through high-volume paddlewheel zones or pre-dissolved at 20–25 °C for injection through a venturi manifold. Because dissolution releases bisulfate and sulfate and lowers the pH of receiving water, alkalinity must be adjusted with sodium bicarbonate to maintain pH 7.0–8.2 measured according to ISO 10523:2012. A six-beaker jar test using 1 L samples and a paddle stirrer at 60 rpm is used to establish oxidative demand; the dose is increased until the oxidation-reduction potential remains above 650 mV for 3 h when evaluated by ASTM D1498-14. In low-salinity shrimp systems, application rates typically range from 0.15 g/m³ to 0.75 g/m³ of the powder, but the field dose must be corrected for dissolved organic carbon, manure solids, and soil-driven oxygen demand. The oxidation reaction is sufficiently aggressive that the compound must not be combined in the same dosing line with potassium permanganate, sodium thiosulfate, or hypochlorite donors. Post-treatment aeration is maintained for a minimum of 6 h to prevent localized oxygen depletion from oxidized organic matter, and ponds are monitored for pH rebound using field probes calibrated against ISO 10523:2012 buffer standards. The absence of free chlorine residue avoids chloramine formation, but the acidic dissolution behavior means that mixer tanks, injection nozzles, and distribution piping should be fabricated from EPDM, PTFE, or PVC rather than unlined mild steel.
In broiler, turkey, and layer houses, the powder is dissolved to a stock solution of 25–250 g/L and delivered into drinking water through positive-displacement diaphragm pumps with EPDM or PTFE wetted parts. Final in-water concentrations are commonly set between 25 ppm and 100 ppm during sanitation cycles, with a contact time of 30–60 min before flushing. Residual oxidation capacity decays rapidly when exopolysaccharide biofilms and iron-reducing bacteria line the inside of polyethylene drinker pipes; the same nominal dose may produce less than 40% of expected residual after 20 min in heavily fouled lines. For that reason, a clean-line verification step is performed by monitoring redox potential at the farthest drinker station using a portable ORP meter under ASTM D1498-14, with a target value above 550 mV during the entire contact window. The stock solution pH is typically 1.5–2.5 at 1% w/v, so the tank and injection valves must be acid-compatible, and the diluted water must not be withheld for more than 24 h after mixing because available oxygen declines with time and temperature. Organic matter, bicarbonate alkalinity, and transition metals create a pseudo-first-order decay profile in field water, but the slope of the decay curve changes batch to batch when biofilms slough from pipe walls. The process is therefore monitored through paired samples taken at the injection point and at the end of the line, with the difference expressed as residual loss per 100 m of pipe. The compound is not a substitute for mechanical line cleaning when biofilm depth exceeds 1 mm; in that case, the system is first treated with a surfactant-alkaline cleaner or high-pressure air scour to remove the polysaccharide matrix.
| Standard | Test orientation | Pass criterion |
|---|---|---|
| EN 1276:2019 | Quantitative suspension test for bactericidal activity | Minimum 5 log reduction at 20 °C, contact 30 min, dirty conditions |
| EN 1656:2019 | Veterinary bactericidal activity in suspension | Minimum 5 log reduction at 10 °C, contact 30 min, interfering substance |
| EN 14675:2015 | Virucidal activity in veterinary area | Minimum 4 log reduction at 10 °C, contact 60 min |
| ASTM D1498-14 | Oxidation-reduction potential of water | Field verification of ORP above 550 mV at farthest drinker |
| ISO 10523:2012 | pH measurement of stock and diluted solutions | Stock pH 1.5–2.5; diluted water pH 6.5–7.5 after buffering |
Dry granular intermediates for on-farm wash-water and boot-dip preparation are diluted at ratios between 1:200 and 1:500 by weight in water at 20–30 °C. In premix production, the active powder is blended with anhydrous sodium sulfate, anhydrous citric acid, and low-alkalinity sodium bicarbonate in a horizontal ribbon blender with a fill ratio of 0.55–0.65. The active particle fraction is controlled to a D50 of 150–250 µm because finer particles increase dust generation and triboelectric charging, while coarser particles segregate toward the top of the batch during discharge. Bulk density differences between the sulfate carrier and the active triple salt produce demixing during pneumatic transfer after blending; this is controlled by keeping blend volume below 70% of bin capacity and by using mass-flow hoppers with 60° cone angles. Residual moisture in the blended premix is held at ≤0.5% by Karl Fischer titration because moisture above 1.0% initiates premature acid-base reaction and causes caking in foil-lined kraft bags. The premix is intended for environmental sanitation, footwear dips, and equipment washing, not for oral feed medicament; direct ingestion of the active powder would expose mucosal tissue to an oxidative load that is not justified by any established veterinary nutritional requirement. Static charge on the finished blend is monitored with a surface potential meter, and the target value is below 0.5 kV before filling. If static charge exceeds this limit, ionizing bars are installed at the outlet of the packer and relative humidity is raised to 45–55% in the filling room to dissipate surface charge without hydrating the carbonate component.
Formulated footbath tablets containing 40–60 wt% active triple salt are compressed on a rotary tablet press with an average compression force of 12–18 kN for a 20 g tablet. Tablet breaking force is measured according to USP <1217>, with a target range of 80–120 N; friability is evaluated by USP <1216> at 100 revolutions and must remain below 0.8%. The conflict in manufacture is between mechanical durability and dissolution rate. A harder tablet above 120 N may survive transport but can require more than 5 min to disintegrate in 10 L of tap water at 15 °C, leaving undissolved particles that clog the boot-dip drain. A softer tablet below 80 N disintegrates quickly but fractures during bulk handling, increasing dust exposure and giving variable dose weights. The granulation endpoint before compression is therefore controlled by loss-on-drying at ≤0.8%; if residual moisture exceeds 1.5%, the acid and carbonate components begin pre-reaction, producing pitted tablet surfaces, reduced hardness, and premature gas release inside the blister pack. The effervescent pair is selected to provide a gas-to-mass ratio of 0.35–0.45 mL/g of carbon dioxide liberated in excess water, which is sufficient to break the tablet matrix without creating foam overflow in a 10 L footbath unit. Packaging is done in cold-form foil or aluminum strip packs immediately after compression because open storage at relative humidity above 60% causes surface grazing and oxidation loss within 24 h. On multi-age farms, footbath stations are refreshed after every 80–100 animal passages or when visible organic loading exceeds 5 g/L of suspended manure solids, whichever occurs first.
Truck-wash bays and equine trailer disinfection usually apply the compound as a low-pressure foam or coarse mist at 0.25–0.5% w/v through stainless-steel air-assisted nozzles with droplet diameter ≥200 µm. The large droplet size is specified to limit inhalation exposure during fogging and to keep the wet film on vertical surfaces for the required residence time. On brushed concrete, the contact time is set at 10–15 min, and the surface must not be allowed to dry before rinsing with potable water at 40–60 bar. The foaming action of the triple salt is limited, so when foam expansion above 3:1 is needed, a nonionic foam stabilizer is added separately; amine-based surfactants are avoided because of accelerated oxidative decomposition and heat generation. Disinfection efficacy for these applications is supported by EN 1656:2019 under dirty conditions, with the working solution temperature maintained at or above 10 °C because contact killing declines sharply in cold water. Stainless steel spray rigs, EPDM hoses, and polypropylene lance extensions are used because the acidic working solution removes zinc from galvanized fittings and produces visible corrosion within days on untreated aluminum. After rinsing, the wash bay floor is allowed to drain for 15 min before reintroducing animals; this reduces the chance of hoof contact with residual acidic film. For wheel-dip troughs at biosecure entry points, the solution is replaced every 7 days or after rainfall introduces visible sediment, and the used solution is discharged only after neutralization to pH 6.5–8.0 because direct release of acidic oxidizer into farm drainage can reduce receiving-water pH and upset biological treatment systems.
In field kits and hatchery sanitation stations, the powder is filled into hydroxypropyl methylcellulose capsules solely as unit-dose packaging for water-line or footbath preparation, not as an oral dosage form. The capsule must dissolve within 3 min in 1 L of water at 15 °C; gelatin is avoided because it softens and cross-links under residual acidic moisture and may fail to release the powder predictably. Capsule fillers with dosator-type heads are run at reduced speed because the abrasive inorganic particles increase pin wear and because static charge causes powder adhesion to plastic funnels unless grounding is applied. A typical filled weight is 2.5 g in a size 00 capsule, sufficient for preparing 10 L of working solution at 0.25% w/v. The capsule shell adds no functional disinfection value beyond dose accuracy and must be free of dyes that could stain porous surfaces or alter the redox reading. Storage of filled capsules requires desiccated packaging with an internal relative humidity below 30%; if moisture ingress occurs, the capsule shell may become tacky and the powder may react with trace organic residues inside the shell. The filled capsules are not acceptable for oral administration because the same oxidative capacity that disinfects water would injure oral and esophageal mucosa, and published data for safe oral exposure in target animal species is limited. This dosage form is therefore restricted to use as a non-ingested, water-soluble unit package where accurate single-dose handling is required and where loose powder would create dust exposure in enclosed hatchery feed rooms.
The raw material is sometimes listed for injectable formulation screening, but the acidic and oxidative properties of the triple salt fail parenteral acceptability before a viable formulation can be proposed. At 1% w/v, the solution pH is 2.0–2.5, and the oxidation-reduction potential measured by ASTM D1498-14 is typically above 850 mV; both values are incompatible with normal tissue pH and with the reducing environment required to protect cellular proteins and lipid membranes. In an injectable matrix, the active oxygen would degrade antioxidant excipients such as sodium metabisulfite or ascorbic acid, and the resulting exotherm could destabilize the finished product during autoclaving. The strong oxidizer would also attack natural rubber closures, certain silicone tubing, and stainless-steel filling needles at the concentrations needed for a meaningful antimicrobial effect. Published data for this specific configuration in injectable veterinary products is limited, and no pharmacopoeial monograph supports the use of unmodified peroxymonosulphate as a parenteral active ingredient. The appropriate manufacturing response is to reject injectable use at the formulation screening stage and to redirect the material to environmental sanitization, water treatment, or surface disinfection, where the oxidative mechanism can be applied without requiring physiological compatibility. No injectable veterinary dosage form can be justified unless a carrier matrix is developed to isolate the oxidizer before administration and release it only after dilution; no such matrix appears in current public veterinary formulation literature.
Competitive Compound Peroxymonosulphate Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Compound peroxymonosulphate powder veterinary grade API for tablets, injections, capsules, powders, granules, premix, and solutions is supplied as a white to off-white free-flowing triple salt comprising two moles of potassium hydrogenperoxymonosulfate, one mole of potassium hydrogen sulfate, and one mole of potassium sulfate; the CAS registry number for the triple salt is 70693-62-8. The product is not a simple KHSO₅ crystal but a stabilized acidic mixed salt in which the active oxidizing species is the peroxymonosulphate anion HSO₅⁻. In the dry state at controlled relative humidity below 40%, the material remains free-flowing and is sized for direct incorporation into the indicated dosage forms. Commercially, model nomenclature is manufacturer-specific; a representative veterinary-grade code is PMS-V, with subgrades PMS-VF for fine-milled use in capsules and injectable solutions, PMS-VM for direct-compression tablet blends, and PMS-VG for granular premix. These codes are not harmonized, so the batch release specification, not the model label, defines suitability. The theoretical active oxygen of the 2:1:1 triple salt is approximately 5.2%; routine veterinary grades are released with available oxygen not less than 4.5% and KHSO₅ content in the range 42.0–50.0% by iodometric titration.
Release testing is organized around four functional attributes: oxidation capacity, oral/injectable purity, particle size, and packaging stability. Because no pharmacopoeial monograph specific to compound peroxymonosulphate is currently published in USP or Ph. Eur., specifications are derived from producer certificates of analysis and cross-referenced to general compendial chapters. Table 1 lists a representative release profile for a powder intended for multiple dosage forms. Values in the table are supplier-specific acceptance limits rather than pharmacopoeial requirements, and registration in a specific jurisdiction requires confirmation against the relevant VICH or regional authority data package.
| Attribute | Typical specification | Reference method |
|---|---|---|
| Appearance | White to off-white crystalline powder | Visual against reference |
| KHSO₅ assay | 42.0–50.0% | Iodometric titration |
| Available oxygen | ≥4.5% | Iodometric titration |
| pH, 1% aqueous solution, 25°C | 2.0–2.5 | USP <791> |
| Loss on drying | ≤0.5% | USP <731> |
| Bulk density | 0.80–1.10 g/cm³ | USP <616> Method I |
| Particle size D50 | 100–250 µm | ISO 13320:2020 laser diffraction |
| Residue on ignition | ≤0.3% | USP <281> |
| Elemental impurities | Pb ≤5 mg/kg, Cd ≤1 mg/kg, As ≤3 mg/kg, Hg ≤1 mg/kg | ICP-MS per ICH Q3D |
| Total aerobic microbial count | ≤100 CFU/g | Ph. Eur. 2.6.12 |
| Endotoxin, injectable grade | ≤0.25 EU/mg | USP <85> |
The iodometric titration endpoint is specific to the peroxymonosulphate anion; chlorinated impurities and hydrogen peroxide must be absent or below the method interference threshold. For injectable application, the powder is further controlled for insoluble particulate matter by USP <788> and conductivity of the reconstituted solution. Particle-size distribution is critical not only for flow and filling, but for segregation in premix blends: a D90 above 425 µm reduces adhesion to carrier particles, while a D10 below 50 µm may generate dust and loss to filters during solution preparation.
Compaction of this API into tablets proceeds most reliably by dry granulation or direct compression because the monopersulfate triple salt liberates oxygen in the presence of aqueous granulation fluid and heat. The powder is blended with anhydrous dibasic calcium phosphate or microcrystalline cellulose dried to moisture ≤0.5%; magnesium stearate is used at 0.5–1.0% but total lubricant contact time is kept below 5 min to limit hydrophobic film build-up. Tablet tooling is maintained at room temperature, and compression rooms are held at ≤35% RH and 20–25°C. Roller-compacted granules containing the API are milled to a mean granule size of 350–800 µm; finer granules improve tablet weight uniformity but increase oxidative dust. Hardness values of finished tablets are formulation-dependent and are not specified globally; published data for this specific configuration is limited. Hard-shell capsule filling is performed with powders of D90 ≤250 µm to avoid bridging; gelatin capsules are replaced with HPMC capsules when moisture exchange across the shell is a concern. Sachet powders and effervescent granules are filled in low-moisture lines under dry nitrogen and closed with desiccant sachets.
For sterile injectable formulations, the API is dissolved in Water for Injection at a concentration typically 10–50 g/L depending on the veterinary indication, and the solution is passed through a 0.2 µm sterilizing-grade polyethersulfone filter. The pH of the bulk solution is adjusted with trisodium citrate or phosphate buffer if tissue tolerance requires a final pH above 4.0; however, raising pH above 5.0 accelerates peroxymonosulphate decomposition and shortens hold time. Terminal sterilization by autoclaving is generally avoided because the peroxymonosulphate anion decomposes under typical 121°C cycles; aseptic filtration is the standard manufacturing route. Solutions are protected from light and stored at 2–8°C; in-use solution stability is evaluated at 20–25°C and commonly limited to 8 h under closed container conditions. Off-gassing oxygen can cause stopper movement if container headspace is insufficient; therefore, closure integrity and headspace volume are monitored during stability studies.
For premix formulations, the API is dispersed with hydrophilic fumed silica at 0.2–0.5% and adsorbed onto spray-dried lactose or calcium carbonate carriers. Ribbon blender or tumble-blender times are set by assay uniformity; for a 500 kg batch, mixing time of 10–15 min at 60–70% vessel fill may be sufficient, but validation by stratified sampling is required. Segregation is measured by relative standard deviation of KHSO₅ assay across 10 sampling ports; release criterion is typically RSD ≤5.0%. The bulk density mismatch between the API and many carriers promotes segregation; this is controlled by matching carrier particle size to the API D50 or by adding 0.5–1.0% mineral oil as a binding film. In double-cone blending, tumble speeds are set below 12 rpm for 100 kg batches to reduce surface free-fall velocity differences. Granulation trials on a top-spray fluid bed with inlet air at 45°C and product temperature 30–35°C have produced granules with acceptable KHSO₅ retention after 20–25 min drying; however, aqueous binder solutions depress local pH and initiate oxygen loss, so binder level is kept below 2.0% of dry granule mass.
The dry powder is thermally stable under controlled storage below 25°C; accelerated decomposition becomes measurable above 40°C, and the product should not be exposed to temperatures above 50°C for more than 24 h. Storage at relative humidity above 60% causes caking and gradual oxygen loss because moisture mediates intramolecular reaction with the potassium hydrogen sulfate component. The package is therefore a double polyethylene liner inside a fiber drum or a sealed aluminum foil pouch; desiccant is included when storage humidity exceeds 60%.
The oxidation potential of the peroxymonosulphate anion is +1.85 V vs SHE under acidic conditions, which is higher than hypochlorous acid and slightly above hydrogen peroxide; this explains rapid oxidative action but also restricts compatible excipients. Excipients with primary or secondary amine groups, sulfide-bearing amino acids, thiosulfate, sulfite, metabisulfite, and ascorbic acid are incompatible. Lactose is acceptable in dry mixes for short shelf-life products, but lactose monohydrate contributes bound water and can increase caking under high-humidity conditions; mannitol or anhydrous calcium hydrogen phosphate is preferred for moisture-sensitive formulations. Transition metal ions, notably Fe²⁺ and Cu²⁺, catalyze radical formation and should be excluded from solution formulations. Chloride-containing matrices may generate chlorine in acidic aqueous systems, so sodium chloride should not be combined with this API in acidified tanks if pH falls below 2.5.
Unlike sodium hypochlorite, calcium hypochlorite, or chloramine-T, the compound does not introduce free available chlorine into the finished solution except when chloride is deliberately added. This avoids typical chloramine and trihalomethane residues in drinking-water applications, although oxidative by-products include sulfate and potassium. The acidic pH of a 1% solution distinguishes it from sodium percarbonate, which raises pH and may precipitate hardness cations in hard water; therefore, buffered formulation studies are required if co-administered with acid-labile actives.
| Product or active moiety | Physical form | Active oxygen or chlorine | pH of use dilution | Principal residue or by-product | Veterinary formulation implication |
|---|---|---|---|---|---|
| Compound peroxymonosulphate triple salt | Solid | 4.5–5.2% active oxygen | 2.0–2.5 for 1% solution | Sulfate, potassium, oxygen | Dry stable; acidic solution; avoid moist granules and amine-containing excipients |
| Hydrogen peroxide 35% | Liquid | 16.5% active oxygen for 35% solution | 3.0–4.0 | Water, oxygen | Liquid dosing; requires vented storage and pump compatibility; no dry premix option |
| Sodium percarbonate | Solid | 13.0–14.0% active oxygen | 10.5–11.0 | Sodium carbonate, oxygen, water | Alkaline; raises pH; useful where mixed oxidant plus alkalinity is desired |
| Sodium hypochlorite 10–15% | Liquid | 10–15% available chlorine | 11–13 | Chloride, chlorate, chloramines | Corrosive; volatile chlorine odor; not suitable for acid-mixed solid dosage lines |
| Calcium hypochlorite | Solid | 65–70% available chlorine | 10–11 | Calcium carbonate scale, chloride | High chlorine load; caking and exothermic response with organic material |
| Chloramine-T | Solid | 24–26% available chlorine | 8–10 | Toluene sulfonamide residue | Slower oxidative kinetics; residue may complicate withdrawal data |
Field formulations for disinfectant footbaths are prepared at 0.5–1.0% w/v, while drinking-line sanitization may use 0.1–0.2% w/v for brief exposure; these figures are starting points for water-quality-specific validation and are not universal dosing instructions. In aquaculture, published work with potassium monopersulphate has reported pond oxidation rates of 0.5–2.0 mg/L, but efficacy against specific pathogens is dependent on organic load, pH, temperature, and contact time. Published data for this specific configuration is limited; controlled challenge studies are required for each target pathogen.